Latest Research
All publications from the Cancer3.AI database, newest first.
Case Report: Sellar hemangioblastoma mimicking a pituitary macroadenoma: a diagnostic and surgical pitfall.
Li J, et al
Researchers report a rare case of sellar hemangioblastoma, an unusually blood-rich brain tumor, that was mistaken for a common pituitary macroadenoma in a 64-year-old woman presenting with dizziness. Preoperative MRI imaging was misinterpreted, leading surgeons to attempt a minimally invasive endoscopic removal, during which they encountered severe, life-threatening bleeding that prevented complete tumor removal. Only after surgery did pathology confirm the true diagnosis: a WHO Grade I hemangioblastoma, a tumor type almost never found in this brain region. A retrospective look at the imaging revealed warning signs that had been overlooked, including prominent blood vessel shadows and unusually rapid contrast enhancement, both characteristic of highly vascular tumors. This case highlights that surgeons and radiologists must consider hemangioblastoma when evaluating any sellar mass, and that recognizing these imaging red flags should prompt preoperative embolization to reduce bleeding risk. Additionally, any confirmed sellar hemangioblastoma should trigger testing for Von Hippel-Lindau disease, a hereditary condition that can fundamentally change the treatment approach.
Frontiers in oncology
Source →Case Report: Cerebellar ALK+ ALCL: diagnostic challenges and therapeutic innovation.
Hao Z, et al
Researchers from China present the first reported adult case of cerebellar ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), an extremely rare T-cell cancer of the central nervous system, in a 35-year-old male patient. The patient was initially misdiagnosed with infectious encephalitis due to overlapping symptoms, brain imaging findings, and cerebrospinal fluid results, delaying correct treatment. Only after progressive neurological deterioration despite antibiotic and antiviral therapy was a brain biopsy performed, confirming the lymphoma diagnosis with a high tumor proliferation index of 60%. Treatment with alectinib, a targeted ALK inhibitor known to penetrate the blood-brain barrier, led to rapid clinical improvement and significant shrinkage of the tumor on imaging. This case underscores the critical importance of early biopsy for atypical brain lesions and highlights how molecularly targeted therapies can dramatically alter outcomes for patients with rare brain malignancies.
Frontiers in oncology
Source →Monte Carlo simulation of uveal melanoma treatment by ocular plaque brachytherapy using gold nanoparticles.
Moeini SM, et al
Researchers used Monte Carlo computer simulations to investigate how gold nanoparticles (GNPs) can improve the effectiveness of ocular plaque brachytherapy — a standard treatment for uveal melanoma, a rare but potentially fatal eye cancer. The study modeled a 14 mm COMS plaque loaded with three different radioactive seed types (iodine-125, palladium-103, and cesium-131) and calculated how adding GNPs at concentrations of 5 to 30 mg of gold per gram of tissue altered the radiation dose delivered to the tumor and surrounding eye structures. Results showed that GNPs significantly boosted the dose reaching the tumor, with cesium-131 producing the greatest enhancement — up to 170% increase at the tumor apex and over 377% within the tumor volume at the highest GNP concentration tested. Importantly, GNPs also reduced unwanted radiation exposure to healthy eye structures such as the lens, with palladium-103 showing lens dose reductions of up to 33% at the highest concentration. These findings suggest that combining GNPs with ocular brachytherapy could allow shorter treatment times while better protecting healthy tissue, potentially improving outcomes and reducing side effects for uveal melanoma patients.
Radiation and environmental biophysics
Source →Atypical Lacrimal Drainage System Granulomas Masquerading as Lacrimal Neoplasms - SALDO update study (SUP) - Paper VII.
Bothra N, et al
A new study published in the journal Orbit examined rare and unusual cases of granulomatous disease affecting the lacrimal drainage system — the tiny channels that drain tears from the eye into the nose — which can closely mimic cancerous tumors. Researchers retrospectively analyzed five biopsy-confirmed cases collected over two years (August 2023 to September 2025), with patients averaging 62.4 years of age. The conditions identified included xanthogranuloma, sclerosing and non-sclerosing forms of non-specific orbital inflammatory disease, and fungal granulomas, all of which presented in ways that could easily be mistaken for malignancy. The study found that careful clinical assessment, a high degree of diagnostic suspicion, and definitive histopathological (tissue) examination are essential tools for distinguishing these benign inflammatory conditions from true cancer. This work is clinically important because misdiagnosing these rare lesions as tumors could lead to unnecessary and potentially harmful treatments, while correct identification allows for appropriate, targeted therapy. Clinicians are advised to consider granulomatous disease in the differential diagnosis when evaluating unusual lacrimal sac masses.
Orbit (Amsterdam, Netherlands)
Source →Primary malignant melanoma of the uterine cervix: a case report of aggressive progression despite multimodal therapy.
Yu Q
Researchers report a rare and aggressive case of primary malignant melanoma arising in the uterine cervix, a cancer so uncommon that treatment guidelines remain largely undefined. A 73-year-old woman diagnosed with early-stage, NRAS Q61K-mutant cervical melanoma underwent radical surgery followed by adjuvant immunotherapy with the anti-PD-1 drug Toripalimab, yet her disease progressed rapidly despite these interventions. Subsequent salvage treatment with a MEK inhibitor — a targeted therapy designed to block the NRAS-driven signaling pathway — also failed to control the disease, and the patient died 17 months after her initial diagnosis. The sequential failure of both immunotherapy and targeted therapy reveals a dual layer of resistance that distinguishes mucosal melanomas from the more common skin-based form of the disease. These findings underscore an urgent need to move beyond single-agent adjuvant approaches and instead design clinical trials testing upfront combination strategies, such as immunotherapy paired with MEK or CDK4/6 inhibitors, for patients with this high-risk malignancy.
Frontiers in oncology
Source →